Clinical Trial: Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07284979) titled 'Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes' on Dec. 09.

Brief Summary: The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: Obesity

Intervention: DRUG: KAI-9531

SC Injection

DRUG: Semaglutide

SC Injection

DRUG: Placebo

SC Injection

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Kailer...